Evidence map›Paper›PMID 39606688›Full record

ReviewTransplant international : official journal of the European Society for Organ Transplantation2024

Angiotensin II Type-1 Receptor Antibody in Solid Organ Transplantation - Is It Time to Test?

Paul James Patrick Martin, Michelle Willicombe, Candice Roufosse

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Transplant international : official journal of the European Society for Organ Transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Paul James Patrick MartinDepartment of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, United Kingdom.
Michelle WillicombeDepartment of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, United Kingdom.
Candice RoufosseDepartment of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiotensin II type-1 receptor antibody (AT1R-Ab) has been mooted as a potential effector of both acute and chronic antibody mediated rejection (AMR). A growing body of literature on the topic is now coming under scrutiny in the context of the evolving Banff AMR diagnostic classification system and refinement of recommendations for histocompatibility testing by the Sensitization in Transplantation Assessment of Risk (STAR) workgroup. This mini-review discusses the latest understanding of pathophysiological mechanisms, clinical evidence for the pathogenicity of AT1R-Ab, and methods of laboratory testing.

Indexed as

Graft RejectionOrgan TransplantationReceptor, Angiotensin, Type 1Histocompatibility TestingHumansKidney TransplantationReceptor, Angiotensin, Type 1antibody mediated rejectionAT1RAT1R antibodynon-HLA antibodyrejection

Identifiers

PMID39606688
PMCPMC11598415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.